Drug Profile
BBB 022
Latest Information Update: 17 Nov 2006
Price :
$50
*
At a glance
- Originator Eisai Co Ltd; Nonindustrial source
- Developer Nonindustrial source
- Class Anti-ischaemics; Neuroprotectants
- Mechanism of Action Cyclic AMP phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemia
Most Recent Events
- 16 Mar 1998 Preclinical development for Ischaemia in USA (Unknown route)